CRL Form 144: Insider Notice to Sell 800 Shares Worth $125,600

Form 144 notice for Charles River Laboratories (CRL) discloses a proposed sale of 800 shares of common stock through UBS Financial Services (Weehawken, NJ) with an aggregate market value of $125,600.

Rhea-AI Filing Summary

Form 144 notice for Charles River Laboratories (CRL) discloses a proposed sale of 800 shares of common stock through UBS Financial Services (Weehawken, NJ) with an aggregate market value of $125,600. The shares represent part of outstanding common stock of 49,120,000 and an approximate sale date of 08/18/2025 on the NYSE. The filing shows the shares were acquired as Performance Stock Units on 01/27/2023 from Charles River Laboratories and that payment at sale is expected in cash. The filer previously sold 400 shares on 08/07/2025 for $59,991. The notice includes the customary attestation that the seller is unaware of undisclosed material adverse information.

Insights

Securities/Insider Transactions Analyst

TL;DR: Routine insider disclosure of planned sale of equity received as performance awards; transaction appears procedural, not material.

The Form 144 documents a proposed sale of 800 common shares by an insider via UBS, with shares acquired as Performance Stock Units on 01/27/2023. The disclosure is consistent with Rule 144 reporting requirements and includes a recent smaller sale of 400 shares on 08/07/2025 generating $59,991. There is no earnings, debt, or operational data in the filing to suggest a material change to the company’s fundamentals; the filing primarily notifies the market of an intended resale of restricted or control securities.

Corporate Governance & Compliance Specialist

TL;DR: Compliance-focused filing showing adherence to resale notice rules; no governance red flags evident from the notice alone.

The document supplies required information: broker name, number of shares, acquisition date and nature (Performance Stock Unit), and a seller attestation about material information. The presence of a prior sale within the past three months is disclosed. Absent other disclosures in this form, there is no indication of insider trading policy breaches or undisclosed corporate events; this is a standard Rule 144 resale notice for regulatory transparency.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filed for CRL disclose?

The notice discloses a proposed sale of 800 common shares via UBS with aggregate market value of $125,600, expected on 08/18/2025.

Who acquired the securities and how were they acquired?

The shares were acquired on 01/27/2023 as Performance Stock Units from Charles River Laboratories.

Has the seller made recent share sales in the past three months?

Yes. The filing reports a sale of 400 shares on 08/07/2025 for $59,991 by Joseph LaPlume c/o Charles River Laboratories.

Through which broker will the proposed sale be executed?

UBS Financial Services Inc. (1000 Harbor Blvd, Weehawken, NJ) is listed as the broker.

Does the filing state whether payment will be in cash?

Yes. The form indicates cash as the nature of payment at sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/18/2025 - 01:27 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001767215
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Charles River Laboratories
SEC File Number	001-15943
Address of Issuer	251 Balardvale Street Wilmington MASSACHUSETTS 01887
Phone	781-222-6000
Name of Person for Whose Account the Securities are To Be Sold	Joseph LaPlume
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	800	125600	49120000	08/18/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	01/27/2023	PERFORMANCE STOCK UNIT	CHARLES RIVER LABORATORIES			8342	08/18/2025	CASH

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Joseph LaPlume c/o Charles River Laboratories 251 Balardvale Street Wilmington MA 01887	Common	08/07/2025	400	59991

144: Remarks and Signature

Remarks
Date of Notice	08/18/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/JOSEPH CASSIDY, for UBS Financial Services Inc, as attorney-in-fact for Joseph LaPlume
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)